{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:11:33Z","timestamp":1768565493229,"version":"3.49.0"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1212\/con.0000000000000730","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T14:16:02Z","timestamp":1559571362000},"page":"793-814","source":"Crossref","is-referenced-by-count":20,"title":["Pediatric Central Nervous System Demyelinating Diseases"],"prefix":"10.1212","volume":"25","author":[{"given":"Tanuja","family":"Chitnis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.12.008"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000309"},{"issue":"3","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report","volume":"86","author":"Chitnis T","year":"2016","unstructured":"Chitnis T Ness J Krupp L. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016;86(3):245\u2013252. doi:10.1212\/WNL.0000000000002283.","journal-title":"Neurology"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24409"},{"issue":"4","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/WNL.0000000000001179","article-title":"Acute idiopathic transverse myelitis in children: early predictors of relapse and disability","volume":"84","author":"Deiva K","year":"2015","unstructured":"Deiva K Absoud M Hemingway C. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology 2015;84(4):341\u2013349. doi:10.1212\/WNL.0000000000001179.","journal-title":"Neurology"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70045-X"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513484547"},{"issue":"11","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/archneur.65.11.1434","article-title":"Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells","volume":"65","author":"Korporal M","year":"2008","unstructured":"Korporal M Haas J Balint B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol 2008;65(11):1434\u20131439. doi:10.1001\/archneur.65.11.1434.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0433-y"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512471878"},{"issue":"5","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaapos.2011.05.020","article-title":"Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies","volume":"15","author":"Waldman AT","year":"2011","unstructured":"Waldman AT Stull LB Galetta SL. Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS 2011;15(5):441\u2013446. doi:10.1016\/j.jaapos.2011.05.020.","journal-title":"J AAPOS"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514526943"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24938"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514551453"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000339482.84392.bd"},{"issue":"10","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000344163.65326.48","article-title":"Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis","volume":"72","author":"Bonhomme GR","year":"2009","unstructured":"Bonhomme GR Waldman AT Balcer LJ. Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. Neurology 2009;72(10):881\u2013885. doi:10.1212\/01.wnl.0000344163.65326.48.","journal-title":"Neurology"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000524"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512445944"},{"issue":"18","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1212\/01.wnl.0000260609.11357.6f","article-title":"Acute transverse myelitis in childhood: center-based analysis of 47 cases","volume":"68","author":"Pidcock FS","year":"2007","unstructured":"Pidcock FS Krishnan C Crawford TO. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007;68(18):1474\u20131480. doi:10.1212\/01.wnl.0000260609.11357.6f.","journal-title":"Neurology"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738030180060601"},{"issue":"2","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.71.2.272","article-title":"Efficacy of high dose steroid therapy in children with severe acute transverse myelitis","volume":"71","author":"Defresne P","year":"2001","unstructured":"Defresne P Meyer L Tardieu M. Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry 2001;71(2):272\u2013274. doi:10.1136\/jnnp.71.2.272.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"e_1_3_1_23_2","first-page":"S46","article-title":"Pediatric transverse myelitis","volume":"87","author":"Absoud M","year":"2016","unstructured":"Absoud M Greenberg BM Lim M. Pediatric transverse myelitis. Neurology 2016;30;87(9 suppl 2):S46\u2013S52. doi:10.1212\/WNL.0000000000002820.","journal-title":"Neurology"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004312"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516631038"},{"issue":"1","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0120","article-title":"Characteristics of children and adolescents with multiple sclerosis","volume":"138","author":"Belman AL","year":"2016","unstructured":"Belman AL Krupp LB Olsen CS. Characteristics of children and adolescents with multiple sclerosis. Pediatrics 2016;138(1). doi:10.1542\/peds.2016-0120.","journal-title":"Pediatrics"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508101933"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.365"},{"issue":"9","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1212\/WNL.0b013e3182a2ce0e","article-title":"T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients","volume":"81","author":"Balint B","year":"2013","unstructured":"Balint B Haas J Schwarz A. T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology 2013;81(9):784\u2013792. doi:10.1212\/WNL.0b013e3182a2ce0e.","journal-title":"Neurology"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90609"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24364"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2013.06.004"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2008.505"},{"issue":"9","key":"e_1_3_1_35_2","first-page":"S74","article-title":"Pediatric multiple sclerosis: clinical features and outcome","volume":"87","author":"Waldman A","year":"2016","unstructured":"Waldman A Ness J Pohl D. Pediatric multiple sclerosis: clinical features and outcome. Neurology 2016;87(9 suppl 2):S74\u2013S81. doi:10.1212\/WNL.0000000000003028.","journal-title":"Neurology"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517719150"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067597"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431725"},{"issue":"9","key":"e_1_3_1_39_2","first-page":"S82","article-title":"Pediatric multiple sclerosis: cognition and mood","volume":"87","author":"Amato MP","year":"2016","unstructured":"Amato MP Krupp LB Charvet LE. Pediatric multiple sclerosis: cognition and mood. Neurology 2016;87(9 suppl 2):S82\u2013S87. doi:10.1212\/WNL.0000000000002883.","journal-title":"Neurology"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514526942"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800149"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511430704"},{"issue":"12","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0b013e318288694e","article-title":"International Pediatric MS Study Group Clinical Trials Summit: meeting report","volume":"80","author":"Chitnis T","year":"2013","unstructured":"Chitnis T Tardieu M Amato MP. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology 2013;80(12):1161\u20131168. doi:10.1212\/WNL.0b013e318288694e.","journal-title":"Neurology"},{"issue":"8","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11940-016-0420-7","article-title":"Use of disease-modifying therapies in pediatric MS","volume":"18","author":"Simone M","year":"2016","unstructured":"Simone M Chitnis T. Use of disease-modifying therapies in pediatric MS. Curr Treat Options Neurol 2016;18(8):36. doi:10.1007\/s11940-016-0420-7.","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","article-title":"Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study","volume":"28","author":"Tenembaum SN","year":"2013","unstructured":"Tenembaum SN Banwell B Pohl D. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol 2013;28(7):849\u2013856. doi:10.1177\/0883073813488828.","journal-title":"J Child Neurol"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.01.023"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000188"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000570"},{"issue":"2","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1212\/WNL.0000000000000576","article-title":"B-cell depletion in children with neuroimmunologic conditions: the learning curve","volume":"83","author":"Chitnis T","year":"2014","unstructured":"Chitnis T Waubant E. B-cell depletion in children with neuroimmunologic conditions: the learning curve. Neurology 2014;83(2):111\u2013112. doi:10.1212\/WNL.0000000000000576.","journal-title":"Neurology"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2007.08.001"},{"issue":"4","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2006-924723","article-title":"Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a","volume":"37","author":"Pakdaman H","year":"2006","unstructured":"Pakdaman H Fallah A Sahraian MA. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics 2006;37(4):257\u2013260. doi:10.1055\/s-2006-924723.","journal-title":"Neuropediatrics"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a2cc4a"},{"issue":"4","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek B","year":"2013","unstructured":"Kornek B Aboul-Enein F Rostasy K. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol 2013;70(4):469\u2013475. doi:10.1001\/jamaneurol.2013.923.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_54_2","first-page":"715","volume-title":"Continuum (Minneap Minn)","author":"Gross RH","year":"2019","unstructured":"Gross RH Corboy JR. Monitoring, switching, and stopping disease-modifying therapies. Continuum (Minneap Minn) 2019;25(3 Multiple Sclerosis and Other CNS Inflammatory Diseases): 715\u2013735."},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2014.02.007"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a8164c"},{"issue":"1","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1275345","article-title":"Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis","volume":"42","author":"Kornek B","year":"2011","unstructured":"Kornek B Bernert G Rostasy K. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics 2011;42(1):7\u201312. doi:10.1055\/s-0031-1275345.","journal-title":"Neuropediatrics"},{"issue":"9","key":"e_1_3_1_59_2","first-page":"S88","article-title":"MRI in the evaluation of pediatric multiple sclerosis","volume":"87","author":"Banwell B","year":"2016","unstructured":"Banwell B Arnold DL Tillema JM. MRI in the evaluation of pediatric multiple sclerosis. Neurology 2016;87(9 suppl 2):S88\u2013S96. doi:10.1212\/WNL.0000000000002787.","journal-title":"Neurology"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30158-8"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517695469"},{"issue":"4","key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh EA","year":"2011","unstructured":"Yeh EA Waubant E Krupp LB. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 2011;68(4):437\u2013444. doi:10.1001\/archneurol.2010.325.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_63_2","first-page":"773","volume-title":"Continuum (Minneap Minn)","author":"Langer-Gould AM","year":"2019","unstructured":"Langer-Gould AM. Pregnancy and family planning in multiple sclerosis. Continuum (Minneap Minn) 2019;25(3 Multiple Sclerosis and Other CNS Inflammatory Diseases):773\u2013792."},{"issue":"9","key":"e_1_3_1_64_2","first-page":"S103","article-title":"Pediatric multiple sclerosis: escalation and emerging treatments","volume":"87","author":"Chitnis T","year":"2016","unstructured":"Chitnis T Ghezzi A Bajer-Kornek B. Pediatric multiple sclerosis: escalation and emerging treatments. Neurology 2016;87(9 suppl 2):S103\u2013S109. doi:10.1212\/WNL.0000000000002884.","journal-title":"Neurology"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.249"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515572406"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003318"},{"issue":"9","key":"e_1_3_1_70_2","first-page":"S59","article-title":"Neuromyelitis optica spectrum disorders in children and adolescents","volume":"87","author":"Tenembaum S","year":"2016","unstructured":"Tenembaum S Chitnis T Nakashima I. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 2016;87(9 suppl 2):S59\u2013S66. doi:10.1212\/WNL.0000000000002824.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud M","year":"2015","unstructured":"Absoud M Lim MJ Appleton R. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015;86(4):470\u2013472. doi:10.1136\/jnnp-2014-308550.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318214332c"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000314832.24682.c6"},{"issue":"3","key":"e_1_3_1_74_2","first-page":"224","article-title":"Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population","volume":"57","author":"Amorim AL","year":"2017","unstructured":"Amorim AL Cabral NC Osaku FM. Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. Rev Bras Reumatol Engl Ed 2017;57(3):224\u2013228. doi:10.1016\/j.rbre.2016.09.016.","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"5","key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer SF","year":"2007","unstructured":"Roemer SF Parisi JE Lennon VA. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(pt 5):1194\u20131205. doi:10.1093\/brain\/awl371.","journal-title":"Brain"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1116-7"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2057"},{"issue":"9","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob A","year":"2009","unstructured":"Jacob A Matiello M Weinshenker BG. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128\u20131133. doi:10.1001\/archneurol.2009.175.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516678474"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13186"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315622819"},{"issue":"4","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/NXI.0000000000000046","article-title":"Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children","volume":"1","author":"Longoni G","year":"2014","unstructured":"Longoni G Banwell B Filippi M Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 2014;1(4):e46. doi:10.1212\/NXI.0000000000000046.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8590-0"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810381445"},{"issue":"5","key":"e_1_3_1_85_2","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien YC","year":"2017","unstructured":"Tien YC Yen HH Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol 2017;35(5):831\u2013836.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"e_1_3_1_86_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.radcr.2016.06.003","article-title":"Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review","volume":"11","author":"Kelly D","year":"2016","unstructured":"Kelly D Monaghan B McMahon E. Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review. Radiol Case Rep 2016;11(3):251\u2013254. doi:10.1016\/j.radcr.2016.06.003.","journal-title":"Radiol Case Rep"},{"issue":"7","key":"e_1_3_1_87_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi C","year":"2011","unstructured":"Costanzi C Matiello M Lucchinetti CF. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77(7):659\u2013666. doi:10.1212\/WNL.0b013e31822a2780.","journal-title":"Neurology"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514525870"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512439439"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098192"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7991-1"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517694086"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7925-y"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-155"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.01.035"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826845fe"},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515587751"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.07.028"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002844"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.03.019"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000089"},{"key":"e_1_3_1_104_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0717-1"},{"key":"e_1_3_1_105_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1814"},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4601"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201906000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:58:53Z","timestamp":1752155933000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1212\/CON.0000000000000730"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000730","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}